Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Kiadis calls up Cytosen
University of Central Florida's Cytosen has been acquired in an all-stock deal by Kiadis Pharma, in a transaction potentially worth up to $70m.
Merck tackles $773m Tilos acquisition
Merck & Co will pay up to $773m to acquire biopharmaceutical developer Tilos Therapeutics, based on research at Harvard Medical School and Brigham & Women’s Hospital.
Salesforce processes $15.7bn Tableau acquisition
Stanford spinout Tableau Software has agreed to a $15.7bn all-stock acquisition by Salesforce, six years after completing a $254m initial public offering on the New York Stock Exchange.
Eriez activates majority role in FaultCurrent
Eriez is now the largest shareholder in Cardiff University-founded power fault protection technology spinout FaultCurrent, having previously invested a seven-figure sum.
Bio-Techne sweeps up B-Mogen
Bio-Techne has bought University of Minnesota-founded genome editing platform operator B-Mogen Biotechnologies to solidify a business relationship that dates to 2016.
Daily deal net: June 5, 2019
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Twitter absorbs Fabula AI
USI-founded fake news detection technology developer Fabula AI has been scooped up by Twitter, which will employ the spinout's talent to remove spam and abuse from its platform.
Ultrahaptics and Leap Motion to fuse operations for $30m
Bristol-founded haptics platform developer Ultrahaptics is set to absorb Leap Motion's patents and employees, succeeding in a transaction that Apple failed to complete twice.

Other News

Woodford dumps OSI stake
Fund manager Neil Woodford has sold his entire stake in Oxford Sciences Innovation, worth close to $70m, as his funds have come under increasing pressure.
Personalis embodies $115m IPO
Personalis has filed to list on the Nasdaq Global Market through an offering that would come eight years after the genome sequencing platform was spun out of Stanford University.
OssDsign surpasses IPO target
Karolinska Development-backed regenerative implant producer OssDsign has booked $15.8m after selling out the original issue for its forthcoming listing, and is now looking to generate up to $2.4m from the overallotment.
Bicycle Therapeutics squares $60.7m IPO circle
Cambridge Innovation Capital has celebrated an exit as Bicycle Therapeutics successfully lists in the US.
Exit of the Year: Ziylo
After a year of countless exits in the ecosystem, many among the most significant yet – so much so that five nominees were not enough to recognise them all – the Award for Exit of the Year was one of the most difficult to determine.
Clevertar clutches onto $275,000
The board at Flinders University-founded medical avatar software platform Clevertar has agreed to pump in funding to clear the spinout's outstanding liabilities to creditors including the university.

Editor's Picks

Otsuka takes up Veryan’s acquisition offer
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Novo pens $800m Ziylo acquisition
Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg